Literature DB >> 34825269

Quantitative evaluation of hepatic fibrosis by fibro Scan and Gd-EOB-DTPA-enhanced T1 mapping magnetic resonance imaging in chronic hepatitis B.

Qingtao Li1, Tianyou Chen1, Nannan Shi2, Wen Ye2, Min Yuan1, Yuxin Shi3.   

Abstract

PURPOSE: Studies have found that both FibroScan (FS) and Gd-EOB-DTPA-enhanced T1 mapping magnetic resonance imaging (Gd-MRI) could assess liver fibrosis (LF) with high effectiveness. The aim of this study is to compare their accuracy in the quantitative evaluation of LF in patients with chronic hepatitis B (CHB), and to explore the diagnostic accuracy of their combination.
METHODS: 160 patients with CHB were included in this study. FS and Gd-MRI were performed within 3 months before the pathological LF staging, which was classified according to the Scheuer-Ludwig scale. The liver stiffness measurement (LSM) was obtained by FS. T1 mapping images of the liver before and 20 min after enhancement were obtained by Look-Locker Gd-MRI.
RESULTS: There were 45, 35, 31 and 49 patients with stage S1, S2, S3 and S4 LF, respectively. LSM increased and the reduction rate of T1 relaxation time of 20 min (rrT120min%) decreased with the severity of LF. The area under curve (AUC) of LSM, rrT120min% and LSM + rrT120min% for the diagnosis of ≥ S2 LF were 0.892, 0.811 and 0.900, respectively. The AUC for ≥ S3 LF was 0.883, 0.838 and 0.899, respectively. The AUC for S4 LF was 0.882, 0.894 and 0.928, respectively.
CONCLUSION: The diagnostic accuracy of FS is better than that of Gd-MRI in the evaluation of ≥ S2 stage LF. The combination of these two methods significantly improved the diagnostic efficiency in the evaluation of S4 stage LF.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  FibroScan; Gd-EOB-DTPA; Hepatitis B, chronic; Liver fibrosis; T1 mapping

Mesh:

Substances:

Year:  2021        PMID: 34825269     DOI: 10.1007/s00261-021-03300-8

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  36 in total

Review 1.  MR contrast agents in hepatic cirrhosis and chronic hepatitis.

Authors:  Luis Martí-Bonmatí
Journal:  Semin Ultrasound CT MR       Date:  2002-02       Impact factor: 1.875

2.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors:  Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal:  Lancet       Date:  2012-12-10       Impact factor: 79.321

3.  Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement.

Authors:  Richard G Barr; Giovanna Ferraioli; Mark L Palmeri; Zachary D Goodman; Guadalupe Garcia-Tsao; Jonathan Rubin; Brian Garra; Robert P Myers; Stephanie R Wilson; Deborah Rubens; Deborah Levine
Journal:  Radiology       Date:  2015-06-16       Impact factor: 11.105

4.  Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models.

Authors:  Miloslav Polasek; Bryan C Fuchs; Ritika Uppal; Daniel T Schühle; Jamu K Alford; Galen S Loving; Suguru Yamada; Lan Wei; Gregory Y Lauwers; Alexander R Guimaraes; Kenneth K Tanabe; Peter Caravan
Journal:  J Hepatol       Date:  2012-05-24       Impact factor: 25.083

5.  Diffusion and Intravoxel Incoherent Motion MR Imaging-based Virtual Elastography: A Hypothesis-generating Study in the Liver.

Authors:  Denis Le Bihan; Shintaro Ichikawa; Utaroh Motosugi
Journal:  Radiology       Date:  2017-06-12       Impact factor: 11.105

6.  Differentiation of healthy from cirrhotic livers. Evaluation of parametric images after contrast administration in magnetic resonance imaging.

Authors:  L Martí-Bonmatí; L Masiá; C Casillas; C L Ronchera-Oms; C Torrijo
Journal:  Invest Radiol       Date:  1996-12       Impact factor: 6.016

Review 7.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

8.  MnDPDP enhancement characteristics and differentiation between cirrhotic and noncirrhotic livers.

Authors:  L Martí-Bonmatí; E Lonjedo; C Poyatos; C Casillas
Journal:  Invest Radiol       Date:  1998-10       Impact factor: 6.016

9.  MR imaging in liver cirrhosis: classical and new approaches.

Authors:  Luis Martí-Bonmatí; Fructuoso Delgado
Journal:  Insights Imaging       Date:  2010-08-05

10.  Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study.

Authors:  Rohit Loomba; Tanya Wolfson; Brandon Ang; Jonathan Hooker; Cynthia Behling; Michael Peterson; Mark Valasek; Grace Lin; David Brenner; Anthony Gamst; Richard Ehman; Claude Sirlin
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.